参考文献

参考文献

［1］Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249.

［2］Bai R，Huang H，Li M，et al.Temporal trends in the incidence and mortality of skin malignant melanoma in China from 1990 to 2019［J］.J Oncol，2021，2021：9989824.

［3］中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组.皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0［J］.中华肿瘤杂志，2020，42（2）：81-93.

［4］Zhang J，Si L，Guo J.Comments on national guidelines for diagnosis and treatment of melanoma 2022 in China（English version）［J］.Chin J Cancer Res，2022，34（6）：635-636.

［5］Cancer Genome Atlas N.Genomic classification of cutaneous melanoma［J］.Cell，2015，161（7）：1681-1696.

［6］Swetter SM，Thompson JA，Albertini MR，et al.NCCN guidelines insights：melanoma：cutaneous，version 2.2021［J］.J Natl Compr Canc Netw，2021，19（4）：364-376.

［7］Newell F，Kong Y，Wilmott JS，et al.Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets［J］.Nat Commun，2019，10（1）：3163.

［8］Hayward NK，Wilmott JS，Waddell N，et al. Whole-genome landscapes of major melanoma subtypes［J］.Nature，2017，545（7653）：175-180.

［9］Rao PK，Barker C，Coit DG，et al.NCCN guidelines insights：uveal melanoma，version 1.2019［J］.J Natl Compr Canc Netw，2020，18（2）：120-131.

［10］Agarwala SS，Eggermont AM，O'Day S，et al.Metastatic melanoma to the liver：a contemporary and comprehensive review of surgical，systemic，and regional therapeutic options［J］.Cancer，2014，120（6）：781-789.

［11］Wei X，Wu D，Li H，Zhang R，et al.The clinicopathological and survival profiles comparison across primary sites in acral melanoma［J］.Ann Surg Oncol，2020，27（9）：3478-3485.

［12］Lian B，Cui CL，Zhou L，et al.The natural history and patterns of metastases from mucosal melanoma：an analysis of 706 prospectivelyfollowed patients［J］.Ann Oncol，2017，28（4）：868-873.

［13］Grossniklaus HE.Understanding uveal melanoma metastasis to the liver：the zimmerman effect and the zimmerman hypothesis［J］.Ophthalmology，2019，126（4）：483-487.

［14］Conway JW，Rawson RV，Lo S，et al.Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites［J］.J Immunother Cancer，2022，10（9）：e004884.

［15］Balasubramanya R，Selvarajan SK，Cox M，et al.Imaging of ocular melanoma metastasis［J］.Br J Radiol，2016，89（1065）：20160092.

［16］Cui C，Mao L，Chi Z，Si L，et al.A phaseⅡ，randomized，doubleblind，placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma［J］.Mol Ther，2013，21（7）：1456-1463.

［17］Robert C，Grob JJ，Stroyakovskiy D，et al.Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma［J］.N Engl J Med，2019，381（7）：626-636.

［18］Robert C，Ribas A，Schachter J，et al. Pembrolizumab versus ipilimumab in advanced melanoma（KEYNOTE-006）：post-hoc 5-year results from an open-label，multicentre，randomised，controlled，phase 3 study［J］.Lancet Oncol，2019，20（9）：1239-1251.

［19］Larkin J，Chiarion-Sileni V，Gonzalez R，et al.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma［J］.N Engl J Med，2019，381（16）：1535-1546.

［20］Tawbi HA，Schadendorf D，Lipson EJ，et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma［J］.N Engl J Med，2022，386（1）：24-34.

［21］Li S，Wu X，Yan X，et al.Toripalimab plus axitinib in patients with metastatic mucosal melanoma：3-year survival update and biomarker analysis［J］.J Immunother Cancer，2022，10（2）：e004036.

［22］Arance A，de la Cruz-Merino L，Petrella TM，et al.PhaseⅡLEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination［J］.J Clin Oncol，2023，41（1）：75-85.

［23］Chesney JA，Ribas A，Long GV，et al.Randomized，double-blind，placebo-controlled，global phaseⅢtrial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma［J］. J Clin Oncol，2023，41（3）：528-540.

［24］Mao L，Ding Y，Bai X，et al. Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral／cutaneous melanoma administered dabrafenib plus trametinib：long-term follow-up of a multicenter，single-arm phaseⅡa trial［J］.Front Oncol，2021，11：720044.(https://www.daowen.com)

［25］Si L，Zhang X，Shu Y，et al.Pembrolizumab in Chinese patients with advanced melanoma：3-year follow-up of the KEYNOTE-151 study［J］.Front Immunol，2022，13：882471.

［26］Zhou L，Shao L，Gao S，et al.Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy［J］.Br J Dermatol，2023，188（1）：112-121.

［27］Bhave P，Ahmed T，Lo SN，et al.Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma［J］.J Immunother Cancer，2022，10（7）：e004668.

［28］Nakamura Y，Namikawa K，Kiniwa Y，et al.Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma：A retrospective，multicenter study of 254 Japanese patients［J］.Eur J Cancer，2022，176：78-87.

［29］Wolchok JD，Chiarion-Sileni V，Gonzalez R，et al.Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma：a pooled analysis［J］.J Clin Oncol，2017，35（2）：226-235.

［30］Hamid O，Robert C，Ribas A，et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma：a post-hoc analysis of KEYNOTE-001，002，006［J］.Br J Cancer，2018，119（6）：670-674.

［31］Bai X，Shoushtari AN，Betof Warner A，et al.Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma：an international multicentre observational study［J］.Br J Dermatol，2022，187（3）：401-410.

［32］Hauschild A，Larkin J，Ribas A，et al.Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600- mutated metastatic melanoma：pooled analysis of 4 randomized clinical trials［J］.JAMA Oncol，2018，4（10）：1382-1388.

［33］Pires da Silva I，Lo S，Quek C，et al.Site-specific response patterns，pseudoprogression，and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy［J］.Cancer，2020，126（1）：86-97.

［34］Wang X，Ji Q，Yan X，et al.The impact of liver metastasis on anti-PD-1 monoclonal antibody monotherapy in advanced melanoma：analysis of five clinical studies［J］.Front Oncol，2020，10：546604.

［35］Tumeh PC，Hellmann MD，Hamid O，et al.Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC［J］.Cancer Immunol Res，2017，5（5）：417-424.

［36］Shi W.Radiation Therapy for Melanoma［M］.In：Ward WH，Farma JM.Cutaneous Melanoma：Etiology and Therapy.Brisbane（AU）：Codon Publications，2017.

［37］Minami Y，Nishida N，Kudo M. Radiofrequency ablation of liver metastasis：potential impact on immune checkpoint inhibitor therapy［J］.Eur Radiol，2019，29（9）：5045-5051.

［38］Veltri A，Calandri M.Thermal ablation and systemic therapies in the metastatic liver：time for a“glocal”approach［J］.Eur Radiol，2019，29（9）：5042-5044.

［39］Shi L，Chen L，Wu C，et al.PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor［J］.Clin Cancer Res，2016，22（5）：1173-1184.

［40］Leyvraz S，Piperno-Neumann S，Suciu S，et al.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma（EORTC 18021）：a multicentric randomized trial［J］.Ann Oncol，2014，25（3）：742-746.

［41］Farolfi A，Ridolfi L，Guidoboni M，et al. Liver metastases from melanoma：hepatic intra-arterial chemotherapy，A retrospective study［J］.J Chemother，2011，23（5）：300-305.

［42］Roger Olofsson Bagge，Axel Nelson，Amir Shafazand，et al.Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases，first results from a phaseⅢrandomized controlled multicenter trial（the SCANDIUM trial）［J］.Journal of Clinical Oncology，2022，40（17＿suppl）：LBA9509.

［43］Jonathan S Zager，Marlana M Orloff，Pier Francesco Ferrucci，et al.Focus phase 3 trial results：Percutaneous hepatic perfusion（PHP）with melphalan for patients with ocular melanoma liver metastases（PHP-OCM-301／301A）［J］.Journal of Clinical Oncology，2022，40（16＿suppl）：9510.

［44］Andtbacka RHI，Collichio F，Harrington KJ，et al.Final analyses of OPTiM：a randomized phaseⅢtrial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stageⅢ-Ⅳmelanoma［J］.J Immunother Cancer，2019，7（1）：145.

［45］Andtbacka RH，Ross M，Puzanov I，et al，Patterns of clinical response with talimogene laherparepvec（T-VEC）in patients with melanoma treated in the OPTiM PhaseⅢClinical Trial［J］.Ann Surg Oncol，2016，23（13）：4169-4177.

［46］Shen L，Qi H，Chen S，et al.Cryoablation combined with transarterial infusion of pembrolizumab （CATAP） for liver metastases of melanoma：an ambispective，proof-of-concept cohort study［J］.Cancer Immunol Immunother，2020，69（9）：1713-1724.

［47］Tong TML，Burgmans MC，Speetjens FM，et al. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma：first safety and efficacy data from the phaseⅠb part of the chopin trial［J］.Cardiovasc Intervent Radiol，2023，10：1007.

［48］Chuanliang Cui，Bin Lian，Xuan Wang，et al.Analysis of overall survival（OS）and relapse-free-survival（RFS）in the phaseⅠb clinical trial of anti-PD-1 ab（toripalimab）plus intralesional injection of OrienX010 in stageⅣmelanoma with liver metastases［J］.Journal of Clinical Oncology，2022，40（16＿suppl）：9551.